Opus Genetics Inc, based in Durham, NC, is a pioneering biotechnology company dedicated to developing groundbreaking gene therapies for patients with rare inherited retinal diseases. Backed by the Retinal Degeneration Fund, Opus Genetics combines unparalleled insight and commitment to patient needs with its own programs in numerous rare retinal diseases to create important new AAV-based retinal gene therapies.
With a unique patient-guided approach, Opus Genetics focuses on preserving vision by targeting mutations in genes that cause inherited retinal diseases such as bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa (RP). Led by Dr. Jean Bennett, a renowned scientific founder, the company is dedicated to advancing treatments for blinding diseases and is actively working towards solving many other inherited blinding conditions.
Generated from the website